Pitfalls of Assessing Hepatotoxicity in Trials and Observational Cohorts

Sabin, Caroline A.
March 2004
Clinical Infectious Diseases;3/1/2004 Supplement, Vol. 38, pS56
Academic Journal
The relationship between the use of antiretroviral drugs and the development of hepatic abnormalities has been documented in both randomized controlled trials (RCTs) and observational database studies. Both types of study design are known to have limitations when addressing this issue. Whereas RCTs may enroll a population that is at lower risk for the development of hepatotoxicity, thus underestimating the possible effect of antiretroviral therapy on hepatic abnormalities, observational databases may encompass information from a more heterogeneous group of patients, allowing the drugs to be assessed in a more realistic situation. However, a number of possible biases associated with the use of observational data may limit the conclusions that can be drawn from such studies. I describe some of the benefits and limitations of RCTs and observational data sets when drawing conclusions about the relationship between antiretroviral therapy and the development of hepatic abnormalities.


Related Articles

  • Safety and efficacy of Mangafodipir trisodium in patients with liver lesions and cirrhosis. Martí-Bonmatí, Luis; Fog, Amura F.; de Beeck, Bart Op; Kane, Pauline; Fagertun, Hans; Martí-Bonmatí, Luis // European Radiology;Jul2003, Vol. 13 Issue 7, p1685 

    Mangafodipir trisodium (Mn-DPDP, Teslascan) is a well-tolerated liver contrast agent. Although the enhancement characteristics of the cirrhotic liver after Mangafodipir trisodium administration have been studied, at present there is no published data on the impact that cirrhosis might have on...

  • Liv.52 Ayurvedic Herb Combination Shows Benefit for Liver Cirrhosis in Small Trial. Neustadt, John // HerbalGram;Winter2006, Issue 69, p29 

    The article presents a research which examines the efficacy of Liv.52, a traditional Ayurvedic herbs, on liver cirrhotic patients. The controlled clinical trial was conducted on 36 subjects. All volunteers has liver cirrhosis confirmed by liver biopsy. The study shows that Liv.52 can improve...

  • Needles in Haystacks. Reuben, Adrian // American Journal of Gastroenterology;Nov2007, Vol. 102 Issue 11, p2444 

    Drug-induced liver disease remains a significant problem for physicians caring for patients with this therapeutic complication and for those developing and licensing new drugs. There has been renewed interest recently in drug-induced liver injury (DILI) investigation, with respect to the...

  • Hepatic Safety. Dieterich, Douglas T. // Clinical Infectious Diseases;3/1/2004 Supplement, Vol. 38, pS43 

    Presents a summary of the presentations made during the "Hepatic Safety and HAART" conference held in Santa Barbara, California on June 7 to 9, 2002. Aim of the event to review the effects of antiretroviral drugs on liver; Account of the mechanisms responsible for drug-induced liver injury;...

  • Unexpected interaction between heroin substitute and atazanavir/ritonavir. Appleby, Jason // HIV Australia;Jul-Sep2005, Vol. 5 Issue 1, p28 

    Discusses research being done on the pharmacokinetic interaction between antiretrovirals atazanavir/ritonavir and heroine substitute buprenorphine. Reference to a study by R. D. Bruce et al published in a 2006 issue of "AIDS"; Cases of interaction reported by investigators; Increase in...

  • Low Prevalence of Liver Disease but Regional Differences in HBV Treatment Characteristics Mark HIV/HBV Co-Infection in a South African HIV Clinical Trial. Ive, Prudence; MacLeod, William; Mkumla, Nompumelelo; Orrell, Catherine; Jentsch, Ute; Wallis, Carole L.; Stevens, Wendy; Wood, Robin; Sanne, Ian; Bhattacharya, Debika // PLoS ONE;Dec2013, Vol. 8 Issue 12, p1 

    Background: Hepatitis B virus (HBV) infection is endemic in South Africa however, there is limited data on the degree of liver disease and geographic variation in HIV/HBV coinfected individuals. In this study, we analysed data from the CIPRA-SA ‘Safeguard the household study’ in...

  • Getting Smarter – The Toxicity of Undertreated HIV Infection. Currier, Judith S.; Baden, Lindsey R. // New England Journal of Medicine;11/30/2006, Vol. 355 Issue 22, p2359 

    The author comments on the Strategies for Management of Antiretroviral Therapy (SMART) trial that was carried out to determine whether withholding therapy for long periods would result in human immunodeficiency viruses (HIV)-associated complications. According to the author, the results of the...

  • New, intensive trials planned on heels of Mississippi HIV 'cure'. Dolgin, Elie // Nature Medicine;Apr2013, Vol. 19 Issue 4, p380 

    The article discusses pediatric HIV studies being planned following the publication of a Mississippi case involving an HIV-infected infant that lived for a year even after cessation of antiretroviral therapy. Pediatric infectious disease physician Deborah Persaud and other specialists are...

  • A Randomized Study of Serial Telephone Call Support to Increase Adherence and Thereby Improve Virologic Outcome in Persons Initiating Antiretroviral Therapy. Collier, Ann C.; Ribaudo, Heather; Mukherjee, A. Lisa; Feinberg, Judith; Fischl, Margaret A.; Chesney, Margaret // Journal of Infectious Diseases;10/15/2005, Vol. 192 Issue 8, p1398 

    Background. Adherence to antiretroviral therapy is difficult, and methods to increase it are needed. Methods. We tested the impact of supportive telephone calls in an adherence substudy of a treatment trial. Subjects initiating antiretroviral therapy received either each site's usual adherence...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics